Opening book details…
Can I read Baricitinib and β-Cell Function in Patients with New-Onset Type 1 Diabetes on EtoBox?
Baricitinib and β-Cell Function in Patients with New-Onset Type 1 Diabetes by Michaela Waibel; John M. Wentworth; Michelle So; Jennifer J. Couper; Fergus J. Cameron; Richard J. MacIsaac; Gabby Atlas; Alexandra Gorelik; Sara Litwak; Laura Sanz-Villanueva; Prerak Trivedi; Simi Ahmed; Francis J. Martin; Madeleine E. Doyle; Jessica E. Harbison; Candice Hall; Balasubramanian Krishnamurthy; Peter G. Colman; Leonard C. Harrison; Helen E. Thomas; Thomas W.H. Kay is a Medicine article available to read on EtoBox.
What is Baricitinib and β-Cell Function in Patients with New-Onset Type 1 Diabetes about?
## BACKGROUND Janus kinase (JAK) inhibitors, including baricitinib, block cytokine signaling and are effective disease-modifying treatments for several autoimmune diseases. Whether baricitinib preserves β-cell function in type 1 diabetes is unclear. ## Conclusions In patients with type 1 diabetes of recent onset, daily treatment with baricitinib over 48 weeks appeared to preserve β-cell function as estimated by the mixed-mealstimulated mean C-peptide level. (Funded by JDRF International and others; BANDIT Australian New Zealand Clinical Trials Registry number, ACTRN12620000239965.
Who reads Baricitinib and β-Cell Function in Patients with New-Onset Type 1 Diabetes?
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Michaela Waibel; John M. Wentworth; Michelle So; Jennifer J. Couper; Fergus J. Cameron; Richard J. MacIsaac; Gabby Atlas; Alexandra Gorelik; Sara Litwak; Laura Sanz-Villanueva; Prerak Trivedi; Simi Ahmed; Francis J. Martin; Madeleine E. Doyle; Jessica E. Harbison; Candice Hall; Balasubramanian Krishnamurthy; Peter G. Colman; Leonard C. Harrison; Helen E. Thomas; Thomas W.H. Kay
- Publisher
- Massachusetts Medical Society
- Published
- 2023
- Language
- EN
- Field
- Medicine (Health Sciences)